111 related articles for article (PubMed ID: 32910714)
1. Exploring the radiosensitizing potential of AZD8931: a pilot study on the human LoVo colorectal cancer cell line.
Antognelli C; Palumbo I; Piattoni S; Calzuola M; Del Papa B; Talesa VN; Aristei C
Int J Radiat Biol; 2020 Nov; 96(11):1504-1512. PubMed ID: 32910714
[TBL] [Abstract][Full Text] [Related]
2. [Effect of gefitinib on radiosensitivity of gastric cancer cell lines].
Cao WG; Ma T; Li JF; Li H; Ji YB; Chen XH; Liu BY; Jin YN
Ai Zheng; 2007 Dec; 26(12):1330-5. PubMed ID: 18076795
[TBL] [Abstract][Full Text] [Related]
3. Icotinib hydrochloride enhances the effect of radiotherapy by affecting DNA repair in colorectal cancer cells.
Ma H; Bi J; Liu T; Ke Y; Zhang S; Zhang T
Oncol Rep; 2015 Mar; 33(3):1161-70. PubMed ID: 25572529
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitizing effects of gefitinib at different administration times in vitro.
Zhuang HQ; Sun J; Yuan ZY; Wang J; Zhao LJ; Wang P; Ren XB; Wang CL
Cancer Sci; 2009 Aug; 100(8):1520-5. PubMed ID: 19432883
[TBL] [Abstract][Full Text] [Related]
5. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
[TBL] [Abstract][Full Text] [Related]
6. Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma.
Schütze C; Dörfler A; Eicheler W; Zips D; Hering S; Solca F; Baumann M; Krause M
Strahlenther Onkol; 2007 May; 183(5):256-64. PubMed ID: 17497097
[TBL] [Abstract][Full Text] [Related]
7. The effect of monoclonal antibody cetuximab (C225) in combination with tyrosine kinase inhibitor gefitinib (ZD1839) on colon cancer cell lines.
Yuan HH; Han Y; Bian WX; Liu L; Bai YX
Pathology; 2012 Oct; 44(6):547-51. PubMed ID: 22935976
[TBL] [Abstract][Full Text] [Related]
8. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").
Fukutome M; Maebayashi K; Nasu S; Seki K; Mitsuhashi N
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):528-36. PubMed ID: 16965995
[TBL] [Abstract][Full Text] [Related]
10. [Radiosensitizing effect of erlotinib on human lung adenocarcinoma cell line A549].
Liu XQ; Qiao TK
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):819-23. PubMed ID: 24447478
[TBL] [Abstract][Full Text] [Related]
11. EGFR and β1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion.
Poschau M; Dickreuter E; Singh-Müller J; Zscheppang K; Eke I; Liersch T; Cordes N
Radiother Oncol; 2015 Sep; 116(3):510-6. PubMed ID: 26096850
[TBL] [Abstract][Full Text] [Related]
12. [Gefitinib enhances the radiosensitivity of nasopharyngeal carcinoma cell line CNE2 in vitro].
He BF; Sun AM; Huang BY; Wang WJ; Zheng XK; Luo RC
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(6):991-4. PubMed ID: 21690052
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
14. Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells.
Wang Y; Yang L; Zhang J; Zhou M; Shen L; Deng W; Liang L; Hu R; Yang W; Yao Y; Zhang H; Zhang Z
Int J Oncol; 2018 Oct; 53(4):1667-1680. PubMed ID: 30085332
[TBL] [Abstract][Full Text] [Related]
15. Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib.
Kim JC; Ali MA; Nandi A; Mukhopadhyay P; Choy H; Cao C; Saha D
Indian J Biochem Biophys; 2005 Dec; 42(6):358-65. PubMed ID: 16955736
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.
Tsai YC; Ho PY; Tzen KY; Tuan TF; Liu WL; Cheng AL; Pu YS; Cheng JC
Mol Cancer Ther; 2015 Mar; 14(3):810-20. PubMed ID: 25589492
[TBL] [Abstract][Full Text] [Related]
17. Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.
Barlaam B; Anderton J; Ballard P; Bradbury RH; Hennequin LF; Hickinson DM; Kettle JG; Kirk G; Klinowska T; Lambert-van der Brempt C; Trigwell C; Vincent J; Ogilvie D
ACS Med Chem Lett; 2013 Aug; 4(8):742-6. PubMed ID: 24900741
[TBL] [Abstract][Full Text] [Related]
18. [6]-Gingerol enhances the radiosensitivity of gastric cancer via G2/M phase arrest and apoptosis induction.
Luo Y; Chen X; Luo L; Zhang Q; Gao C; Zhuang X; Yuan S; Qiao T
Oncol Rep; 2018 May; 39(5):2252-2260. PubMed ID: 29512739
[TBL] [Abstract][Full Text] [Related]
19. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
20. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
